MedTrace Logo

Home Test for Measuring Plasma P-tau217 in Alzheimer's Disease

NCT06622135 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-02-11

No results posted yet for this study

Summary

The goal of this is to develop an easy at home test that can be used to assist in diagnosing Alzheimer's disease (AD). The test will use an FDA approved device for at home blood sample collection. The blood samples will be evaluated to determine if the concentration of p-tau217, a biomarker that is elevated in AD patients, measured from blood samples collected using the at home device is comparable to the results obtained from blood samples collected by venipuncture.

Conditions

  • Alzheimer Disease
  • Healthy Subjects

Interventions

DEVICE

Tasso Lancet Device

blood samples will be obtained from all participants using Tasso device

Sponsors & Collaborators

  • Insight Research Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-19
Primary Completion
2024-12-07
Completion
2024-12-07
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06622135 on ClinicalTrials.gov